journal cover

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

Scandinavian Journal of Rheumatology

Mar 7, 2013

Yoshihiro HishitaniAtsushi Kumanogoh

Get paper from

Abstract

The retention of the anti-rheumatic agent tocilizumab (TCZ) has not been well documented in patients with rheumatoid arthritis (RA). We conducted an observational study to compare the retention of TCZ and anti-tumour necrosis factor (TNF) drugs in the treatment of patients with RA. We r...read more

Mentioned in this Paper

Antirheumatic Agents
Monoclonal Antibodies
Rheumatoid Arthritis
Biological Factors
Biological Products
Cox Proportional Hazards Models
Dose-Response Relationship, Drug
Drug Administration Schedule
Incidence Studies
Necrosis
Paper Details
References
  • References28
  • Citations11
123
  • References28
  • Citations11
12

Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis

Scandinavian Journal of Rheumatology

Mar 7, 2013

Yoshihiro HishitaniAtsushi Kumanogoh

PMID: 23470089

DOI: 10.3109/03009742.2012.762037

Abstract

The retention of the anti-rheumatic agent tocilizumab (TCZ) has not been well documented in patients with rheumatoid arthritis (RA). We conducted an observational study to compare the retention of TCZ and anti-tumour necrosis factor (TNF) drugs in the treatment of patients with RA. We r...read more

Mentioned in this Paper

Antirheumatic Agents
Monoclonal Antibodies
Rheumatoid Arthritis
Biological Factors
Biological Products

Related Papers

Paper Details
References
  • References28
  • Citations11
123
  • References28
  • Citations11
12

Get paper from

/papers/retention-of-tocilizumab-and-anti-tumour-necrosis/23470089